Search Result
Results for "
Hypoglycemic
" in MedChemExpress (MCE) Product Catalog:
2
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-N7910
-
-
-
- HY-Y0004
-
-
-
- HY-15383
-
|
Others
|
Others
|
Glyparamide is an orally active chlorophenyl-containing sulfonylurea. Glyparamide shows hypoglycemic activity and rarely causes hepatic injury .
|
-
-
- HY-W011651
-
-
-
- HY-170692
-
|
Akt
PI3K
NF-κB
|
Metabolic Disease
|
Hypoglycemic agent 3 (Compound H26), a derivative of corosolic acid, exhibits lipid-lowering and significant hypoglycemic effects and can be used as a hypoglycemic agent. Hypoglycemic agent 3 inhibits insulin resistance by targeting MCCC1 and can be used in the study of type 2 diabetes .
|
-
-
- HY-130003
-
|
Others
|
Metabolic Disease
|
Hypoglycemic agent 1 acts as a therapeutic and/or prophylactic agent for diabetes. Hypoglycemic agent 1 has an action for lowering blood sugar .
|
-
-
- HY-N3613
-
|
Others
|
Metabolic Disease
|
Conduritol A is a hypoglycemic agent which inhibits the absorption of glucose and can be extracted from Gymnema sylvestre .
|
-
-
- HY-135670B
-
|
Glycosidase
|
Metabolic Disease
|
Glycosidase-IN-2 (Compound 20) is an azasugar class of glycosidase inhibitor. Glycosidase-IN-2 has hypoglycemic activity .
|
-
-
- HY-135670A
-
|
Glycosidase
|
Metabolic Disease
|
β-glycosidase-IN-1 (Compound 33) is a piperidine derivative and a β-glycosidase inhibitor. β-glycosidase-IN-1 has hypoglycemic activity .
|
-
-
- HY-N12241
-
|
Others
|
Others
|
Sterebin F is a steroid isolated from the Stevia rebaudiana leaves. Sterebin F has hypoglycemic activity .
|
-
-
- HY-162893
-
|
Glycosidase
|
Metabolic Disease
|
SX29 is an orally active non-competitive α-glucosidase inhibitor with an IC50 value of 2.12 μM. SX29 exhibits hypoglycemic activity, and oral administration of SX29 can reduce blood glucose levels and improve glucose tolerance in diabetic mice .
|
-
-
- HY-101048
-
|
Bacterial
|
Infection
Metabolic Disease
|
Synthalin A sulfate is a biguanylated diamine with antibacterial and hypoglycemic properties. Synthalin A sulfate against S. aureus with a MIC of 64 μg/mL .
|
-
-
- HY-N7377
-
|
Glycosidase
|
Metabolic Disease
|
Butyl isobutyl phthalate is isolated from the rhizoid of Laminaria japonica. Butyl isobutyl phthalate is a non-competitive α-glucosidase inhibitor with an IC50 value of 38 μM. Butyl isobutyl phthalate shows a hypoglycemic effect and has the potential for diabetes treatment .
|
-
-
- HY-N4147
-
|
Others
|
Metabolic Disease
Inflammation/Immunology
|
Eleutheroside D is an active lignan isolated from the root of Eleutherococcus senticosus, has anti-inflammatory and hypoglycemic activities . Eleutheroside D is an optical isomer of Eleutheroside E (HY-N0272) .
|
-
-
- HY-W011651R
-
|
Phosphatase
|
Metabolic Disease
|
Carbutamide (Standard) is the analytical standard of Carbutamide. This product is intended for research and analytical applications. Carbutamide (BZ-55) is an orally active and first-generation sulfonylurea with hypoglycemic activity .
|
-
-
- HY-113631
-
|
PPAR
|
Neurological Disease
Metabolic Disease
|
Amorfrutin B is a highly potent natural peroxisome proliferation-activated receptor γ (PPARγ) agonist with oral activity with Ki values of 19 nM and EC50 values of 73 nM, respectively. Amorfrutin B has hypoglycemic and neuroprotective activities .
|
-
-
- HY-170588
-
|
Glycosidase
|
Metabolic Disease
|
α-Glucosidase-IN-78 (Compound 12m) is an inhibitor for α-glucosidase with a reversible, competitive IC50 6.0 μM. α-Glucosidase-IN-78 can be used in research of diabete for its hypoglycemic property .
|
-
-
- HY-N12647
-
|
Others
|
Infection
Inflammation/Immunology
|
cis-Hinkiresinol is a bioactive constituent of Rhizoma anemarrhenae. Rhizoma anemarrhenae is reprted to have anti-pathogenic microorganism, hypoglycemic effects, anti-inflammatory, antipyretic effects and anti-platelet aggregation .
|
-
-
- HY-163652
-
|
Others
|
Metabolic Disease
|
Glicetanile is an orally active hypoglycemic agent, that stimulates the release of insulin from pancreatic beta cells, and lowers the blood sugar. Glicetanile exhibits potential in ameliorating the type 2 diabetes .
|
-
-
- HY-135670
-
|
Glycosidase
|
Metabolic Disease
|
Glycosidase-IN-1 (Compound 9) is a glycosidase inhibitor synthesized from D-mannose. Glycosidase-IN-1 be used to synthesize some immunosuppressive agents and β-glucosidase inhibitors. Glycosidase-IN-1 has hypoglycemic activity .
|
-
-
- HY-121565
-
|
Insulin Receptor
|
Metabolic Disease
Endocrinology
|
SaRI 59-801 is an orally effective hypoglycemic compound with stimulation activity of insulin secretion. SaRI 59-801 decreases blood glucose in several species and to elevate plasma insulin in rats and mice .
|
-
-
- HY-N11840
-
|
Glycosidase
|
Metabolic Disease
|
Mortatarin F (Compound 1) is an inhibitor of α‑glucosidase with an IC50 of 8.7 μΜ. Mortatarin F is an renylated flavonoid that can be isolated from mulberry leaves and can be used for hypoglycemic research .
|
-
-
- HY-168706
-
|
Phosphatase
|
Metabolic Disease
|
LXQ-87 is an oral noncompetitive inhibitor of PTP1B with an IC50 of 1.061 μM, showing hypoglycemic activity. LXQ-87 alleviates insulin resistance and promotes cellular glucose uptake, making it useful for research on type 2 diabetes .
|
-
-
- HY-N0661
-
-
-
- HY-122943
-
|
Fungal
Apoptosis
|
Infection
Cancer
|
Moracin D is a flavonoid that can be isolated from Morus alba. Moracin D induces cell apoptosis and shows hypoglycemic, antiadipogenic, antifungal and antitumor effects. Moracin D can be used for fungal infection and breast cancer research .
|
-
-
- HY-126067
-
|
Glycosidase
Apoptosis
|
Inflammation/Immunology
|
(-)-Pinoresinol is a plant-derived tetrahydrofuran lignan that inhibits α-glucosidase and acts as a hypoglycemic agent. (-)-Pinoresinol has some anti-inflammatory effects and acts as a chemopreventive agent, inducing increased apoptosis and cell cycle G2/M arrest .
|
-
-
- HY-156830A
-
|
G protein-coupled Bile Acid Receptor 1
|
Metabolic Disease
|
(4′R)-TGR5 Receptor Agonist 4 is the R enantiomer of TGR5 Receptor Agonist 4 (HY-156830). TGR5 Receptor Agonist 4 is an agonist of Bile Acid Receptor (TGR5), with EC50 for hTGR5 and mTGR5 of 2 nM and 3 nM, respectively. TGR5 Receptor Agonist 4 plays important roles in hypoglycemic and weight loss .
|
-
-
- HY-128923
-
3-Mercaptopicolinic acid hydrochloride; 3-MPA hydrochloride
|
PEPCK
|
Metabolic Disease
|
SKF-34288 (3-Mercaptopicolinic acid) hydrochloride is an orally active phosphoenolpyruvate carboxykinase (PEPCK) inhibitor (Ki: 2-9 μM). SKF-34288 hydrochloride is a potent hypoglycemic agent by inhibiting glucose synthesis. SKF-34288 hydrochloride also inhibits Asn metabolism and increases amino acids and amides .
|
-
-
- HY-N0820
-
Catalpol
Maximum Cited Publications
9 Publications Verification
Catalpinoside
|
HBV
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
Catalpol (Catalpinoside), an iridoid glycoside found in Rehmannia glutinosa. Catalpol has neuroprotective, hypoglycemic, anti-inflammatory, anti-cancer, anti-spasmodic, anti-oxidant effects and anti-HBV effects .
|
-
-
- HY-N0661R
-
-
-
- HY-N8264
-
|
TRP Channel
|
Neurological Disease
Inflammation/Immunology
Cancer
|
Moringin is a potent and selective TRPA1 ion channel natural agonist with an EC50 of 3.14 μM. Moringin does not activate or activates very weakly the vanilloids somatosensory channels TRPV1, TRPV2, TRPV3 and TRPV4, and the melastatin cooling receptor TRPM8. Moringin has hypoglycemic, antimicrobial, anti-inflammatory, anticancer and neuroprotection activities .
|
-
-
- HY-N5086
-
-
-
- HY-N0820R
-
|
HBV
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
Catalpol (Standard) is the analytical standard of Catalpol. This product is intended for research and analytical applications. Catalpol (Catalpinoside), an iridoid glycoside found in Rehmannia glutinosa. Catalpol has neuroprotective, hypoglycemic, anti-inflammatory, anti-cancer, anti-spasmodic, anti-oxidant effects and anti-HBV effects .
|
-
-
- HY-172120
-
|
GPR119
|
Metabolic Disease
|
GPR119 agonist 3 (Compound 21b) is an orally active agonist of GPR119 with an EC50 value of 3.8 nM for hGPR119. Additionally, GPR119 agonist 3 exhibits hypoglycemic effects and can be used in research on type 2 diabetes and obesity .
|
-
-
- HY-W011220
-
ADD-3878; U-63287
|
PPAR
|
Cardiovascular Disease
Cancer
|
Ciglitazone is a potent and selective PPARγ agonist (EC50=3 μM). Ciglitazone inhibits proliferation and differentiation of th17 cells. Ciglitazone is a hypoglycemic agent orally active in the obese-hyperglycemic animal models. Ciglitazone induces apoptosis accompanied by activation of p38 MAPK and nuclear translocation of apoptosis inducing factor (AIF) in opossum kidney (OK) renal epithelial cells .
|
-
-
- HY-150723
-
|
Glycosidase
|
Metabolic Disease
|
PBI-6DNJ is an orally active and potent multivalent glycosidase inhibitor. PBI-6DNJ exhibits good inhibition activity against α-glucosidase from mice, with a Ki of 0.14 μM. PBI-6DNJ exhibits good hypoglycemic activity. PBI-6DNJ can be used for type 2 diabetes research .
|
-
-
- HY-N0416
-
-
-
- HY-U00012
-
SQ 15860; Serbose; Subose
|
Others
|
Metabolic Disease
|
Glyhexamide is an effective hypoglycemic agent in adult diabetics.
|
-
-
- HY-N0416R
-
-
-
- HY-B1103
-
-
-
- HY-B0401S
-
-
-
- HY-B0401S1
-
-
-
- HY-N9725
-
16ξ-Hydroxycleroda-3,13-dien-15,16-olide
|
Dipeptidyl Peptidase
|
Metabolic Disease
|
16-Hydroxycleroda-3,13-dien-15,16-olide (16ξ-Hydroxycleroda-3,13-dien-15,16-olide; HCD), a clerodane diterpene, is a potent serine protease dipeptidyl peptidase 4 (DPP-4) inhibitor. 16-Hydroxycleroda-3,13-dien-15,16-olide down-regulates LPS-induced ERK phosphorylation in myocyte but blocks GLP-1 induced PKA expression. 16-Hydroxycleroda-3,13-dien-15,16-olide exhibits hypolipidemic, hepatoprotective, hypoglycemic efficacy .
|
-
-
- HY-B1429
-
-
-
- HY-N7910R
-
-
-
- HY-N0299
-
-
-
- HY-N6653
-
-
-
- HY-B1429R
-
|
Na+/K+ ATPase
|
Endocrinology
|
Chlorpropamide (Standard) is the analytical standard of Chlorpropamide. This product is intended for research and analytical applications. Chlorpropamide is an oral hypoglycemic agent studied in non-insulin-dependent diabetes mellitus (NIDDM).
|
-
-
- HY-N0205
-
Anemoside B4
|
Others
|
Cancer
|
Pulchinenoside C (Anemoside B4) is Pulsatilla koreana Nakai that have many numerous biological effects in vitro, including enhancing hypoglycemic, anti-tumor, neuroprotective and anti-angiogenic activity.
|
-
-
- HY-B0089
-
BAY g 5421
|
Glycosidase
|
Metabolic Disease
Cancer
|
Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin .
|
-
- HY-N2000
-
|
HIV
|
Infection
Inflammation/Immunology
Cancer
|
Bellidifolin is a xanthone isolated from the stems of Swertia punicea, with hepatoprotective, hypoglycemic, anti-oxidation, anti-inflammatory and antitumor activities . Bellidifolin also acts as a viral protein R (Vpr) inhibitor .
|
-
- HY-B0089A
-
Bay-g 5421 sulfate
|
Glycosidase
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
Acarbose (BAY g 5421) sulfate, antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose sulfate can potentiate the hypoglycemic effects of sulfonylureas or insulin .
|
-
- HY-162758
-
|
Aldose Reductase
|
Metabolic Disease
|
ALR2-IN-5 (Compound 10a) is an inhibitor of ALR2 with an IC50 value of 99.29 nM. ALR2-IN-5 exhibits hypoglycemic effects and can be utilized in research related to diabetes .
|
-
- HY-U00165
-
-
- HY-114683
-
|
TGF-beta/Smad
|
Cardiovascular Disease
|
KS370G is an orally active hypoglycemic and cardiovascular protective agent. KS370G improves left ventricular hypertrophy and function in pressure-overload mice heart. KS370G reduces renal obstructive nephropathy .
|
-
- HY-156830
-
-
- HY-N0807R
-
|
MMP
NF-κB
JAK
Keap1-Nrf2
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
Swertiamarin (Standard) is the analytical standard of Swertiamarin. This product is intended for research and analytical applications. Swertiamarin is an orally active iridoid compound with hypoglycemic, hypolipidemic, anti rheumatic and antioxidant activities, which can be used in the research of diabetes and arthritis .
|
-
- HY-P4860
-
|
Akt
Gli
JNK
PKA
|
Metabolic Disease
|
Adropin (34-76) is a secretory domain of Adropin. Adropin (34-76) can inhibit cAMP level and glucose production in hepatocytes, and has a hypoglycemic effect. Adropin (34-76) plays an antifibrotic role by inhibiting the GLI1 signaling pathway .
|
-
- HY-148529
-
(±)-DG5128 free base; DG5128 free base
|
Adrenergic Receptor
|
Cardiovascular Disease
Metabolic Disease
|
Midaglizole ((±)-DG5128 free base; DG5128 free base) is a potent α2-adrenoceptor antagonist. Midaglizole is a hypoglycemic agent. Midaglizole increases blood pressure and reduces blood glucose levels in vivo .
|
-
- HY-N0655
-
3-O-Methyl-D-chiro-inositol
|
Influenza Virus
|
Infection
Cardiovascular Disease
Inflammation/Immunology
|
D-pinitol (3-O-Methyl-D-chiro-inositol) is a natural compound presented in several plants, like Pinaceae and Leguminosae plants. D-pinitol exerts hypoglycemic activity and protective effects in the cardiovascular system . D-pinitol has antiviral and larvicidal activities .
|
-
- HY-B0089R
-
|
Glycosidase
|
Metabolic Disease
Cancer
|
Acarbose (Standard) is the analytical standard of Acarbose. This product is intended for research and analytical applications. Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin .
|
-
- HY-121323R
-
|
Apoptosis
|
Neurological Disease
Inflammation/Immunology
Cancer
|
Acarbose (Standard) is the analytical standard of Acarbose. This product is intended for research and analytical applications. Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin .
|
-
- HY-162136
-
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
GPR40 agonist 7 (Compound 1) is an orally active G protein-coupled receptor 40 (GPR40) agonist. GPR40 agonist 7 can significantly increase insulin and GLP-1 secretion, and has a hypoglycemic effect in vivo with an ED50 of 0.58 mg/kg
|
-
- HY-117985A
-
DA-1229 hydrochloride
|
Dipeptidyl Peptidase
|
Metabolic Disease
Endocrinology
|
Evogliptin hydrochloride (DA-1229 hydrochloride) is an orally available DPP4 inhibitor with significant and durable hypoglycemic effects in mouse models. Evogliptin hydrochloride also inhibits the generation of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin hydrochloride can be used in the research of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .
|
-
- HY-N2229
-
|
Cytochrome P450
Fungal
Bacterial
|
Infection
Inflammation/Immunology
Cancer
|
Rhapontigenin is a natural analog of resveratrol with anticancer, antioxidant, antifungal and antibacterial activities. Rhapontigenin is amechanism-based, potent and selective cytochrome P450 1A1?inactivator (IC50
?= 400 nM). Rhapontigenin exhibits 400-fold and 23-fold selectivity for P450 1A1 over P450 1A2 and P450 1B1, respectively .
|
-
- HY-N2229R
-
|
Cytochrome P450
Fungal
Bacterial
|
Infection
Inflammation/Immunology
Cancer
|
Rhapontigenin (Standard) is the analytical standard of Rhapontigenin. This product is intended for research and analytical applications. Rhapontigenin is a natural analog of resveratrol with anticancer, antioxidant, antifungal and antibacterial activities. Rhapontigenin is amechanism-based, potent and selective cytochrome P450 1A1 inactivator (IC50
= 400 nM). Rhapontigenin exhibits 400-fold and 23-fold selectivity for P450 1A1 over P450 1A2 and P450 1B1, respectively .
|
-
- HY-N0655R
-
|
Influenza Virus
|
Infection
Cardiovascular Disease
Inflammation/Immunology
|
D-Pinitol (Standard) is the analytical standard of D-Pinitol. This product is intended for research and analytical applications. D-pinitol (3-O-Methyl-D-chiro-inositol) is a natural compound presented in several plants, like Pinaceae and Leguminosae plants. D-pinitol exerts hypoglycemic activity and protective effects in the cardiovascular system . D-pinitol has antiviral and larvicidal activities .
|
-
- HY-144035
-
|
GCGR
|
Cancer
|
GLP-1R agonist 4 is a potent agonist of GLP-1R. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 4 has the potential for the research of diabetes (extracted from patent WO2019239319A1, compound 96) .
|
-
- HY-N7241
-
|
Others
|
Endocrinology
|
Saudin, derived from Clutia lanceolata, is a hypoglycemic compound that significantly enhances glucose-triggered insulin release from murine pancreatic islets. It belongs to a group of new diterpenoids with a distinct tetracyclic core, suggesting potential as a therapeutic agent for diabetes treatment. Proposed biosynthetic pathways outline alternative cyclization routes from a common precursor, with Lanceolide P (16) identified as a promising lead compound for further development in managing diabetes .
|
-
- HY-P10312
-
|
GLP Receptor
|
Metabolic Disease
|
SPN009 (Sequence 3) is a GLP-1 Receptor agonist, with EC50 of 2.84 nM. SPN009 attenuates the type II diabetes in DB/DB mice models .
|
-
- HY-163005
-
|
Glycosidase
|
Metabolic Disease
|
α-Glucosidase-IN-43 (compound AS14) is an α-glucosidase inhibitor (IC50: 4.32 μM) with acute hypoglycemic activity. α-Glucosidase-IN-43 exhibits safety and in vivo efficacy, is nontoxic to normal mouse fibroblasts, and is able to rescue streptozotocin (HY-13753)-induced diabetic rats. α-Glucosidase-IN-43 can be used to study postprandial hyperglycemia in diabetic patients .
|
-
- HY-Y0337
-
Cysteine
|
Endogenous Metabolite
ERK
|
Neurological Disease
Metabolic Disease
Cancer
|
L-Cysteine (Cysteine) is an orally active conditionally essential amino acid with hypoglycemic effects, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine promotes the proliferation and differentiation of neural stem cells via the CBS/H2S pathway. L-Cysteine suppresses ghrelin and reduces appetite in rodents and humans. L-Cysteine can be used as an anorectic agent .
|
-
- HY-144034
-
|
GCGR
|
Metabolic Disease
|
GLP-1R agonist 3 is a potent agonist of GLP-1R. GLP-1R agonist 3 is a thickened imidazole derivative compound. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 3 has the potential for the research of diabetes (extracted from patent WO2021197464A1, compound 1) .
|
-
- HY-144033
-
|
GCGR
|
Metabolic Disease
|
GLP-1R agonist 1 is a potent agonist of GLP-1R. GLP-1R agonist 1 is a thickened imidazole derivative compound. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 1 has the potential for the research of diabetes (extracted from patent WO2021197464A1, compound 4) .
|
-
- HY-144717
-
|
Phosphatase
|
Metabolic Disease
|
PTP1B-IN-18 is an orally active complete mixed type protein tyrosine phosphatase 1B (PTP1B) inhibitor with a Ki of 35.2 μM. PTP1B-IN-18 can be used for type 2 diabetes research .
|
-
- HY-159944
-
|
PPAR
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
PPARγ agonist 14 (compound 3) is a PPARy agonist (EC50=2.4 μM) with anti-diabetic activity. PPARγ agonist 14 can improve intracellular glucose uptake, promote insulin release, and lower blood sugar. In addition, PPARγ agonist 14 also improves mitochondrial function, reduces oxidative stress, and inhibits inflammatory factors. PPARγ agonist 14 can be used in the study of neurodegenerative diseases, neuroinflammatory diseases, and other diseases .
|
-
- HY-N0807
-
|
MMP
NF-κB
JAK
Keap1-Nrf2
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
Swertiamarin is an orally active natural product with hypoglycemic, lipid-lowering, anti-rheumatic, and antioxidant activities. Swertiamarin can regulate the levels of pro-inflammatory cytokines, MMP, and NF-κB, and promote osteoblast proliferation. Swertiamarin has antioxidant and hepatoprotective effects against carbon tetrachloride induced rat liver toxicity through the Nrf2/HO-1 pathway. Swertiamarin can attenuate inflammatory mediators by regulating JAK2/STAT3 transcription factors in adjuvant induced arthritis rats. Swertiamarin can be used in the research of diabetes and arthritis .
|
-
- HY-147246
-
HTD1801; BUDCA
|
Biochemical Assay Reagents
|
Metabolic Disease
|
Berberine ursodeoxycholate (HTD1801), an ionic salt of Berberine and Ursodeoxycholic acid, is an orally active and potent hypolipidemic agent. Berberine ursodeoxycholate shows significantly great reduction in liver fat content. Berberine ursodeoxycholate has a broad spectrum of metabolic activity. Berberine ursodeoxycholate can be used for the research of hyperlipidemia, non-alcoholic steatohepatitis (NASH) and diabetes .
|
-
- HY-126969
-
|
PPAR
|
Metabolic Disease
|
C333H is a selective PPARγ modulator with insulin-sensitizing and hypoglycemic activities. C333H exhibits similar insulin-sensitizing effects to thiazolidinediones (TZDs) in diabetic mouse models without significantly increasing body weight or adipose tissue weight. C333H increases circulating high molecular weight adiponectin isoform levels in diabetic db/db mice, reduces serine phosphorylation of PPARγ 273 in brown adipose tissue, and selectively modulates the expression of specific PPARγ target genes in adipose tissue. Express. C333H exhibits weak recruitment of co-activators and weak dissociation of co-repressors in vitro. These properties suggest that C333H may be a potential inhibitor of type 2 diabetes .
|
-
- HY-144718
-
|
Phosphatase
|
Metabolic Disease
|
PTP1B-IN-17 (Compound 45), a potential selective benzimidazole derivative, acts as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with a Ki of 30.2 μM. PTP1B-IN-17 can be used for the research of type 2 diabetes.
|
-
- HY-144716
-
|
Phosphatase
|
Metabolic Disease
|
PTP1B-IN-19 (Compound 43), a potential selective benzimidazole derivative, acts as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with a Ki of 23.3 μM. PTP1B-IN-19 can be used for the research of type 2 diabetes.
|
-
- HY-144713
-
|
Phosphatase
|
Metabolic Disease
|
PTP1B-IN-16 (Compound 46), a potential selective benzimidazole derivative, acts as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with a Ki of 12.6 μM. PTP1B-IN-16 can be used for the research of type 2 diabetes.
|
-
- HY-P3580
-
Human N-acetyl GIP
|
Insulin Receptor
|
Metabolic Disease
Endocrinology
|
Acetyl Gastric Inhibitory Peptide (human) is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) can be used for research of diabetes, insulin resistance and obesity .
|
-
- HY-P3580A
-
Human N-acetyl GIP TFA
|
Insulin Receptor
|
Metabolic Disease
Endocrinology
|
Acetyl Gastric Inhibitory Peptide (human) TFA is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) TFA can be used for research of diabetes, insulin resistance and obesity .
|
-
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P4860
-
|
Akt
Gli
JNK
PKA
|
Metabolic Disease
|
Adropin (34-76) is a secretory domain of Adropin. Adropin (34-76) can inhibit cAMP level and glucose production in hepatocytes, and has a hypoglycemic effect. Adropin (34-76) plays an antifibrotic role by inhibiting the GLI1 signaling pathway .
|
-
- HY-P3580A
-
Human N-acetyl GIP TFA
|
Insulin Receptor
|
Metabolic Disease
Endocrinology
|
Acetyl Gastric Inhibitory Peptide (human) TFA is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) TFA can be used for research of diabetes, insulin resistance and obesity .
|
-
- HY-P10312
-
|
GLP Receptor
|
Metabolic Disease
|
SPN009 (Sequence 3) is a GLP-1 Receptor agonist, with EC50 of 2.84 nM. SPN009 attenuates the type II diabetes in DB/DB mice models .
|
-
- HY-P3580
-
Human N-acetyl GIP
|
Insulin Receptor
|
Metabolic Disease
Endocrinology
|
Acetyl Gastric Inhibitory Peptide (human) is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) can be used for research of diabetes, insulin resistance and obesity .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0401S
-
|
Tolbutamide-d9 is the deuterium labeled Tolbutamide. Tolbutamide is a first generation potassium channel blocker, sulfonylurea oral hypoglycemic agent.
|
-
-
- HY-B0401S1
-
|
Tolbutamide- 13C is the 13C-labeled Tolbutamide. Tolbutamide is a first generation potassium channel blocker, sulfonylurea oral hypoglycemic agent.
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: